Clinical Trial of Orthokeratology Lens (MCOK-01)
Launched by MENICON CO., LTD. · Sep 7, 2023
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
The test product is the orthokeratology lens, and the control product is a commercially available orthokeratology lens. The number of enrolled subjects is 390, and clinical observation is performed for 12 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with myopia and myopic astigmatism
- • 2. Those who are not willing to wear glasses in daily life
- • 3. Fully understand of the purpose of the clinical trial and agree to sign the informed consent form to participate in clinical trials, based on his/her willingness
- • 4. Those who can visit the institution on scheduled dates
- • 5. Those who can receive guidance and tests as required by the investigator
- • 6. Those who fully understand and follow the instructions of the lenses for this clinical trial
- Exclusion Criteria:
- • \<At screening\>
- • 1. Best corrected vision acuity of less than 0.8 with spectacles
- • 2. Subjective refraction test shows spherical power greater than -6.00D,less than -0.50D or astigmatism greater than 1.5D
- • 3. Patients in need of treatment for eye disease other than refractive error (excluding those receiving artificial tears eye drops due to the wearing of corneal contact lenses)
- • 4. The medical history of intraocular surgery that may affect the effect of wearing the lens for this clinical trial (those with corneal transplantation, Retinal detachment, etc.)
- • 5. The medical history of refractive corneal surgery
- • 6. Those in need of a strength out of the scope of lens for this clinical trial
- • 7. Having eye allergic diseases that may cause disorders in wearing the lenses for this clinical trial
- • 8. All Corneal abnormalities including keratoconus, corneal dystrophy, previous history of ocular herpes infections, acute dry eyes, low corneal endothelial cell counts.
- • 9. Pregnant (judgment according to her known information) or those who plan to become pregnant during clinical trial, or those who are breast feeding
- • 10. Those who are participating in other clinical trials or have participated in other clinical trial in the past 30 days
- • 11. Prior experience with use of rigid lenses within the previous 3 weeks or use of soft lenses within the previous 3 days
- • 12. Prior experience with myopia control treatment (e.g. atropine, orthokeratology, multifocal soft contact lenses)
- • 13. Minor/adult subjects who lack mental capacity
- • 14. Other not suitable for this clinical trial at investigator's discretion \<At the beginning of the wearing\>
- • (1) Those who are determined to be unable to obtain good centralized positioning even though changing strength (2) Pregnancy confirmed (3) Those who are difficult in continuing the clinical trial at investigator's discretion
About Menicon Co., Ltd.
Menicon Co., Ltd. is a leading global company specializing in the development and manufacturing of innovative contact lenses and related ophthalmic products. Established in 1951, Menicon has consistently advanced the field of vision care through rigorous research and development, focusing on enhancing the comfort and health of contact lens wearers. The company is committed to clinical excellence and safety, actively sponsoring clinical trials to evaluate new technologies and products that aim to improve ocular health. With a strong emphasis on quality, sustainability, and customer satisfaction, Menicon continues to play a pivotal role in shaping the future of eye care solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Stan Isaacs
Study Director
I & Vision Research Centre Pte. Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported